SUNRAY-01 A Global Pivotal Study in Participants with KRAS G12C-Mutant Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing FirstLine Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression =50% or LY3537982 and Pembrolizumab Pemetrexed Platinum vs Placebo and Pembrolizumab Pemetrexed Platinum regardless of PD-L1 Expression

Brief description of study

This study is testing two different treatments (LY3537982 in combination with pembrolizumab against a placebo combined with pembrolizumab) for a cancer called KRAS G12C-mutant NSCLC (non-small cell lung cancer). The study has two parts: Part A compares the treatments with one another for patients whose cancer has a marker called PD-L1 at a level of 50% or higher. Part B looks at the same treatments for patients with PD-L1 ranging from 0 to 100%. The decision about which part a patient joins depends on their doctor and what's best for treatment. Before joining, some patients might get one cycle of regular treatment if they really need it. The study also has two different doses of LY3537982 in combination with pembrolizumab, and they're trying to figure out the best amount, comparing different options to see which one works better. Overall, the study team is hoping to find better treatments for this type of lung cancer.


Clinical Study Identifier: s23-01224
ClinicalTrials.gov Identifier: NCT06119581
Principal Investigator: Joshua K Sabari.
Other Investigators: Samantha VanMaanen, Elka R Travis, Salman Rafi Punekar, Jessica Wang, Cristian C Papazoglu Statescu, Elaine Shum, Elise Roughan, Sally Lau, Danny Perlaza, Marissa Rybstein, David Mendoza, Melissa L Martinez, James Newman, Jeffrey G Schneider, Natalia Cherkassky, Kirby Rodriguez, Vamsidhar Velcheti.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.